Real-life treatment of cholinergic urticaria with omalizumab.
暂无分享,去创建一个
M. Maurer | S. Altrichter | M. Metz | M. Chuamanochan | T. Ohanyan | H. Knoth | A. Asady
[1] T. Jakob,et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence , 2017, The Journal of allergy and clinical immunology.
[2] T. Horikawa,et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management , 2018, Clinical Autonomic Research.
[3] M. Maurer,et al. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. , 2017, The Journal of allergy and clinical immunology.
[4] M. Gonçalo,et al. Long‐term management of chronic spontaneous urticaria with omalizumab , 2017, Clinical and experimental dermatology.
[5] M. Maurer,et al. Cholinergic urticaria patients of different age groups have distinct features , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[6] Janko Brand,et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. , 2017, The Journal of allergy and clinical immunology.
[7] S. Thomsen,et al. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients , 2016, The British journal of dermatology.
[8] M. Magerl,et al. An improved Peltier effect‐based instrument for critical temperature threshold measurement in cold‐ and heat‐induced urticaria , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] N. Kohno,et al. Elevated serum IgE against MGL_1304 in patients with atopic dermatitis and cholinergic urticaria. , 2014, Allergology international : official journal of the Japanese Society of Allergology.
[10] M. Maurer,et al. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. , 2014, Journal of dermatological science.
[11] M. Maurer,et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. , 2014, Journal of dermatological science.
[12] S. Mathur,et al. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria , 2013, Allergy and asthma proceedings.
[13] T. Zuberbier,et al. Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria , 2010, International Archives of Allergy and Immunology.
[14] T. Zuberbier,et al. Successful treatment of solar urticaria with anti‐immunoglobulin E therapy , 2008, Allergy.
[15] T. Zuberbier,et al. Successful treatment of cholinergic urticaria with anti‐immunoglobulin E therapy , 2008, Allergy.
[16] A. Levinson,et al. Evaluation of a patient with cold and cholinergic urticaria. , 1979, The Journal of allergy and clinical immunology.